发布时间：2026-05-07 17:09 Highlights:

Chiesi agreed to acquire KalVista Pharmaceuticals for ￥27.00 per share in cash, representing an equity consideration of approximately ￥1.9bn
Acquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s long-term commitment to people living with rare conditions
Transaction expected to close in Q3 2026
PARMA, Italy & FRAMINGHAM, Mass. -- (BUSINESS WIRE) --

Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc. (“KalVista”) (Nasdaq: KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). The Transaction was unanimously approved by both Chiesi’s and KalVista’s Boards of Directors and is expected to close in Q3 2026, subject to the
=*=*=*=*=*=
当前为第1/21页
下一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页